Mizuho lowered the firm’s price target on ResMed (RMD) to $300 from $310 and keeps an Outperform rating on the shares following the fiscal Q1 report. The firm says GLP-1s are not presenting a headwind yet for ResMed while its US competition is stable.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD: